Advisory Boards with Key Opinion Leaders (KOLs)
Everyone recognises the value of Key Opinion Leaders (KOLs) through their research, publications, guidelines/consensus document development, and their participation on pharmaceutical advisory boards. Identifying and developing relationships with global, national and local KOLs requires an invaluable network of advocates to communicate strategies for a pharmaceutical brand prior to market authorisation in Europe.
KOLs are viewed as impartial sources of information, and are often called upon by pharmaceutical companies to provide a realistic assessment of a drug’s effectiveness.
The value of health outcomes and pharmacoeconomic analysis depends largely on the structure of the local healthcare system. In countries where governments negotiate reimbursement levels (e.g. France, Spain and Australia), health outcomes research is essential to demonstrate the cost effectiveness of a new therapy.
Keith Tolley of Tolley Health Economics has several years’ experience attending and participating at both UK and International Advisory Boards. As a health economist and HTA decision maker, Keith can contribute to:
- Health Economics Strategy Advisory Boards: To advise and help prepare your submissions to UK HTA bodies, and to advise you on your economic models to ensure they are fit for purpose.
- Payer Advisory Boards: Assessing reimbursement and market access evidence needs for new drugs (representing the UK).